Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology is presenting 3-year disease-free survival data from its Phase III ExteNET Trial of PB272 in extended adjuvant breast cancer at the 2016 San Antonio Breast Cancer Symposium.

Puma Biotechnology, Inc.